Abstract
Recent studies have suggested that a specific small population of cells termed tumor-initiating cells (TICs) may be intrinsically resistant to therapy including radiation, and may therefore be the primary mediators of recurrence. Numerous targets are being explored using multiple approaches for their involvement in the self-renewal or survival as well as radioresistance of breast TICs. These studies will provide a broad range of compounds to be tested and to develop novel TIC radiosensitizers that will improve clinical outcome and decrease recurrence of cancer after radiation. In this review we will discuss recent efforts to identify and target these cells to selectively radiosensitize them with novel agents, as well as the TIC radiosensitizing potential of current therapies already in clinical use.
Keywords: Breast cancer, Radiation, Cancer stem cells, Tumor-initiating cells
Anti-Cancer Agents in Medicinal Chemistry
Title: Potential Targets for Improving Radiosensitivity of Breast Tumor-Initiating Cells
Volume: 10 Issue: 2
Author(s): Wei Xu, Bisrat G. Debeb, Lara Lacerd and Wendy A. Woodward
Affiliation:
Keywords: Breast cancer, Radiation, Cancer stem cells, Tumor-initiating cells
Abstract: Recent studies have suggested that a specific small population of cells termed tumor-initiating cells (TICs) may be intrinsically resistant to therapy including radiation, and may therefore be the primary mediators of recurrence. Numerous targets are being explored using multiple approaches for their involvement in the self-renewal or survival as well as radioresistance of breast TICs. These studies will provide a broad range of compounds to be tested and to develop novel TIC radiosensitizers that will improve clinical outcome and decrease recurrence of cancer after radiation. In this review we will discuss recent efforts to identify and target these cells to selectively radiosensitize them with novel agents, as well as the TIC radiosensitizing potential of current therapies already in clinical use.
Export Options
About this article
Cite this article as:
Xu Wei, Debeb G. Bisrat, Lacerd Lara and Woodward A. Wendy, Potential Targets for Improving Radiosensitivity of Breast Tumor-Initiating Cells, Anti-Cancer Agents in Medicinal Chemistry 2010; 10(2) . https://dx.doi.org/10.2174/187152010790909362
DOI https://dx.doi.org/10.2174/187152010790909362 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Bioengineering RNA Silencing Across the Life Kingdoms
Recent Patents on Biotechnology Human Serum Albumin Conjugated Biomolecules for Cancer Molecular Imaging
Current Pharmaceutical Design Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy
Current Medicinal Chemistry Disintegrins from Snake Venoms and their Applications in Cancer Research and Therapy
Current Protein & Peptide Science Flavonoids Influence Epigenetic-Modifying Enzyme Activity: Structure-Function Relationships and the Therapeutic Potential for Cancer
Current Medicinal Chemistry Hypertension, Anti-Hypertensive Therapy and Neoplasia
Current Pharmaceutical Design Editorial (Thematic Issue: Personalized Therapy In Cancer of Digestive System)
Clinical Cancer Drugs Free ISG15 and Protein ISGylation Emerging in SARS-CoV-2 Infection
Current Drug Targets Repurposing Chloroquine Analogs as an Adjuvant Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Protease-Activated Receptors (PARs) as Therapeutic Targets: Development of Agonists / Antagonists and Modulation of Gastrointestinal Functions
Drug Design Reviews - Online (Discontinued) Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease
Current Pharmaceutical Design Interrelationships of Circulating Tumor Cells with Metastasis and Thrombosis: Role of MicroRNAs
Current Pharmaceutical Design Undressing the Fungal Cell Wall/Cell Membrane - the Antifungal Drug Targets
Current Pharmaceutical Design Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Laminin-332-Integrin Interaction: A Target For Cancer Therapy?
Current Medicinal Chemistry